Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

U.S. Ulcerative Colitis Market is projected to grow from USD 3.22 Billion in 2025 to USD 4.94 Billion by 2035 Increasing Cases of Ulcerative Colitis in the U.S.Austin, April 16, 2026 (GLOBE NEWSWIRE) ...

Your physical health can affect your mental well-being. Here's how a UC diagnosis specifically might impact your psyche, and ...

Researchers at the University of Michigan Health Rogel Cancer Center discovered a new mechanism for eliminating one of the main side effects of immunotherapy treatment: colitis. Immunotherapy is used ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...